glp-1 drugs and fertility Clinical trials suggest GLP-1s may improve in men with obesity Weight loss drugs may be

In June 2025, Amgen announced positive Phase 2 trial results for MariTide showing up to ~20% weight loss in obese patients and ~17% in type 2 diabetes patients, presented at the ADA 85th scientific sessions

However, what sets GLP-1RAs apart from existing pharmacotherapies is not just their efficacy but their potential to shift how we think about AUD treatment

Sulfites can cause severe allergic reactions that are life threatening to some people who are sensitive to sulfites

Some research suggests GLP-1 signaling may have anti-inflammatory properties in intestinal tissue, which could theoretically benefit IBD

Most patients experience gradual symptom improvement over weeks to months after discontinuation

We see a lot of them having problems with side effects